O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+2.22%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.05B
AUM Growth
+$5.05B
(-3.3%)
Cap. Flow
-$81.2M
Cap. Flow
% of AUM
-1.61%
Top 10 Holdings %
Top 10 Hldgs %
35.6%
Holding
132
New
17
Increased
26
Reduced
29
Closed
15
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
$101M |
| 2 |
Biogen
BIIB
|
$68.6M |
| 3 |
Eli Lilly
LLY
|
$63.9M |
| 4 |
Baxter International
BAX
|
$63.4M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$60M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$117M |
| 2 |
Pfizer
PFE
|
$71.4M |
| 3 |
Natera
NTRA
|
$54M |
| 4 |
UnitedHealth
UNH
|
$49.4M |
| 5 |
89bio
ETNB
|
$46.6M |
Sector Composition
| 1 | Healthcare | 97.56% |
| 2 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $340M | 6.67% | 2,718,735 | – | – |
|
|
2
Enliven Therapeutics
ELVN
$1.2B
| $197M | 3.87% | 8,996,213 +4,609,645 | +105% | +$101M |
|
3
Boston Scientific
BSX
$156B
| $190M | 3.72% | 3,790,000 -108,200 | -3% | -$5.41M |
|
4
Humana
HUM
$36.5B
| $169M | 3.32% | 348,700 | – | – |
|
5
Bristol-Myers Squibb
BMY
$96B
| $162M | 3.18% | 2,340,000 -244,900 | -9% | -$17M |
|
6
Intuitive Surgical
ISRG
$170B
| $159M | 3.11% | 620,500 | – | – |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $157M | 3.08% | 1,615,210 | – | – |
|
|
THRX
8
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $153M | 3% | 17,233,668 | – | – |
|
|
9
Biogen
BIIB
$19.4B
| $140M | 2.76% | 505,000 +246,800 | +96% | +$68.6M |
|
|
10
UnitedHealth
UNH
$281B
| $130M | 2.56% | 276,000 -104,500 | -27% | -$49.4M |
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $119M | 2.34% | 865,100 -107,200 | -11% | -$14.8M |
|
|
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
| $116M | 2.27% | 4,498,900 -751,100 | -14% | -$19.3M |
|
13
Stryker
SYK
$150B
| $105M | 2.06% | 367,600 -113,400 | -24% | -$32.4M |
|
14
Edgewise Therapeutics
EWTX
$1.51B
| $97.2M | 1.91% | 14,567,176 | – | – |
|
15
Evolent Health
EVH
$1.12B
| $94M | 1.84% | 2,895,632 +70,800 | +3% | +$2.3M |
|
16
Terns Pharmaceuticals
TERN
$609M
| $90.2M | 1.77% | 7,619,135 | – | – |
|
|
VRNA
17
Verona Pharma
VRNA
$9.16B
| $85.6M | 1.68% | 4,260,691 -311,598 | -7% | -$6.26M |
|
18
Thermo Fisher Scientific
TMO
$186B
| $85.2M | 1.67% | 147,800 -54,400 | -27% | -$31.4M |
|
19
Ionis Pharmaceuticals
IONS
$6.79B
| $75.9M | 1.49% | 2,124,500 +130,900 | +7% | +$4.68M |
|
20
Compass Therapeutics
CMPX
$483M
| $73.1M | 1.44% | 22,362,850 | – | – |
|
21
Tenet Healthcare
THC
$16.3B
| $72.5M | 1.42% | 1,220,300 | – | – |
|
22
Keros Therapeutics
KROS
$618M
| $71.7M | 1.41% | 1,679,417 | – | – |
|
|
23
Eli Lilly
LLY
$657B
| $63.9M | 1.25% | +186,000 | New | +$63.9M |
|
24
Crinetics Pharmaceuticals
CRNX
$2.92B
| $63.4M | 1.25% | 3,950,796 +753,920 | +24% | +$12.1M |
|
|
25
Baxter International
BAX
$12.7B
| $63.4M | 1.24% | +1,562,000 | New | +$63.4M |
|